Oxabenz 50 Injection
Prescription Required
Product introduction
Oxabenz 50 Injection is used in the treatment of cancer of colon and rectum. It shows its working by stopping or slowing down the growth of cancer cells.
Oxabenz 50 Injection is used to treat cancer
Oxabenz 50 Injection is used to treat cancer
Uses of Oxabenz Injection
Benefits of Oxabenz Injection
In Cancer of colon and rectum
Cancer of the colon and rectum, also known as colorectal cancer (CRC) or bowel cancer, is the development of cancer from two parts of the large intestine, namely, the colon or rectum. In this type of cancer, the person may notice symptoms such as blood in the stool, a change in bowel movements, weight loss, and fatigue. Oxabenz 50 Injection treats and also lowers the risk of developing further cancerous growths (polyps) and bowel cancer. It kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.
Side effects of Oxabenz Injection
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Oxabenz
- Nausea
- Fatigue
- Anemia (low number of red blood cells)
- Vomiting
- Diarrhea
- Decreased white blood cell count (neutrophils)
- Low blood platelets
- Increased liver enzymes
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Stomatitis (Inflammation of the mouth)
How to use Oxabenz Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Oxabenz 50 Injection. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTOR
Oxabenz 50 Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Breast feeding
UNSAFE
Oxabenz 50 Injection is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving
UNSAFE
Oxabenz 50 Injection may cause side effects which could affect your ability to drive.
Oxaliplatin_name$ treatment may result in an increased risk of dizziness, nausea, and vomiting, and other neurological symptoms that affect walking and this may affect your ability to drive.
Oxaliplatin_name$ treatment may result in an increased risk of dizziness, nausea, and vomiting, and other neurological symptoms that affect walking and this may affect your ability to drive.
Kidney
CAUTION
Oxabenz 50 Injection should be used with caution in patients with severe kidney disease. Dose adjustment of Oxabenz 50 Injection may be needed. Please consult your doctor.
Limited information is available on the use of Oxabenz 50 Injection in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
Limited information is available on the use of Oxabenz 50 Injection in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
Liver
CAUTION
Oxabenz 50 Injection should be used with caution in patients with liver disease. Dose adjustment of Oxabenz 50 Injection may be needed. Please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Oxabenz 50 Injection
₹3055.0/Injection
Oxabenz 100 Injection
Admac Pharma Ltd
₹5485/injection
80% costlier
Oxalipine 100mg Injection
Alpine Lifescience Private Limited
₹5222/injection
71% costlier
Oxalipine 50mg Injection
Alpine Lifescience Private Limited
₹2666/injection
13% cheaper
Quick tips
- Oxabenz 50 Injection is given as an injection into veins under the supervision of a doctor.
Fact Box
Chemical Class
Platinum Analogs
Habit Forming
No
Therapeutic Class
ANTI NEOPLASTICS
Action Class
Platinum compounds-Anticancer
Patient concerns
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Chabner BA, Bertino J, Cleary J, et al. Cytotoxic Agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1689-90.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 944.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1034-35.
- Oxaliplatin. Hayes, UK: Ranbaxy (UK) Limited a Sun Pharmaceutical Company; 2011 [19 Apr. 2018]. [Accessed 22 Jan. 2019] (online) Available from:
- Oxaliplatin. Bridgewater, New Jersey: sanofi-aventis U.S; 2002 [revised Oct. 2015]. [Accessed 26 Mar. 2019] (online) Available from:
- Central Drugs Standard Control Organisation (CDSCO). [Accessed 26 Mar. 2019] (online) Available from:
Marketer details
Name: Admac Pharma Ltd
Address: SCO 84, Sector 5, Panchkula (Haryana), 134112 INDIA.
Country of origin: India
Lab tests offered by us
Related/Popular tests
MRP
₹3055
Inclusive of all taxes
25.0 ml in 1 vial
SOLD OUT
Notify me